Compass Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Compass Therapeutics has 5 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceWe have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. ("ABL Bio"), a South Korea-based clinical-stage company focused on developing antibody therapeutics.
CMPX 10-Kaccession 0001171843-25-001106
SentenceThis agreement relates to our license from Adimab for certain antibodies for development and commercialization as biopharmaceutical products, including our product candidate, CTX-471.
CMPX 10-Kaccession 0001171843-25-001106
SentenceIn addition, the S-3 registration statement included a sales agreement with B. Riley Securities, Inc., pursuant to which we could offer and sell shares of our common stock having an aggregate of up to $75 million.
CMPX 10-Kaccession 0001171843-25-001106
SentenceSouth Korean rights are held by Handok Pharmaceuticals, Inc. ("Handok") and China rights were out-licensed to Elpiscience Biopharmaceuticals Co., Limited ("Elpiscience").
CMPX 10-Kaccession 0001171843-26-001337
SentenceSouth Korean rights are held by Handok Pharmaceuticals, Inc. ("Handok") and China rights were out-licensed to Elpiscience Biopharmaceuticals Co., Limited ("Elpiscience").
CMPX 10-Kaccession 0001171843-26-001337
SentenceThe licensing revenue consisted of a $1 million milestone payment from Elpiscience for completing a Phase 1 trial in China.
CMPX 10-Kaccession 0001171843-25-001106
Compass Therapeutics, Inc.
0.79
Expected move
Inputsspot 0.79exp Nov 20ATM strike 1ATM straddle 0.30IV 148%
Largest filed tie
—